Cabaletta Bio, Inc.
CABACabaletta Bio is a late clinical-stage biotechnology company developing engineered T cell therapies designed to provide deep and durable, potentially curative responses for patients with autoimmune diseases.
Table of contents
Earnings
Next report
Aug 6, 2026 (In 3 weeks)Competitors
By market cap
By revenue growth
Profile
Cabaletta Bio is a late clinical-stage biotechnology company developing engineered T cell therapies designed to provide deep and durable, potentially curative responses for patients with autoimmune diseases. The company's proprietary CABA platform utilizes Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) to reset the immune system through the transient depletion of disease-causing B cells. Their lead candidate is currently being evaluated across multiple indications including myositis, systemic lupus erythematosus, and systemic sclerosis.
A specialized clinical-stage developer of CAR T therapies specifically for autoimmune indications, leveraging a proprietary platform and strategic manufacturing partnerships to enable outpatient administration and scalability.
Questions, answered.
- What is Cabaletta Bio, Inc.'s market cap?
- Cabaletta Bio, Inc. (CABA) has a market capitalization of $507.9M and trades on NASDAQ.
- Who are Cabaletta Bio, Inc.'s competitors?
- Cabaletta Bio, Inc.'s key competitors include Kyverna Therapeutics, Novartis, Gilead Sciences, and others. These companies compete in similar markets and product categories.
- Who does Cabaletta Bio, Inc. partner with?
- Cabaletta Bio, Inc.'s notable partners include Cellares Corporation, Oxford Biomedica, Lonza, and others.
- What subsidiaries does Cabaletta Bio, Inc. have?
- Cabaletta Bio, Inc.'s subsidiaries include Cabaletta Bio GmbH, Cabaletta Bio (Germany) GmbH.
- Where is Cabaletta Bio, Inc. headquartered?
- Cabaletta Bio, Inc. is headquartered in United States of America and employs approximately 120 people. It has been publicly traded since 2019.